## Abstract Pristimerin is a natural product derived from the __Celastraceae__ and __Hippocrateaceae__ families that were used as folk medicines for antiinflammation in ancient times. Although it has been shown that pristimerin induces apoptosis in breast cancer cells, the involved mechanism of act
Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells
✍ Scribed by Xiaohua Li; Di Chen; Shuping Yin; Yonghong Meng; Huanjie Yang; Kristin R. Landis-Piwowar; Yiwei Li; Fazlul H. Sarkar; G. Prem Veer Reddy; Q. Ping Dou; Shijie Sheng
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 338 KB
- Volume
- 212
- Category
- Article
- ISSN
- 0021-9541
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Proteasome inhibitors are known to induce apoptosis in a variety of cancer cells. On the other hand, maspin, a non‐inhibitory serine protease inhibitor, is shown to sensitize cancer cells to therapeutic agents that induce apoptosis. We examined the consequence of maspin expression in prostate cancer cells targeted for treatment with various proteasome inhibitors. We observed that proteasome inhibitors induced apoptosis more effectively in maspin transfected human prostate cancer DU145 cells than in control cells. Interestingly, increased apoptosis in these cells was associated with a significant induction of maspin expression. MG‐132, a proteasome inhibitor, induced endogenous and ectopic [cytomegalovirus promoter (CMV)‐driven] maspin expression, and maspin siRNA attenuated MG‐132‐induced apoptosis. Proteasome inhibitor‐induced maspin expression was inhibited by actinomycin D (Act D) and cyclohexamide (CHX), and by the inhibitors of p38MAPK, but not ERK1/2 or NF‐κB. Electrophoretic mobility‐shift assay (EMSA) and promoter‐reporter activity analyses suggested that p38MAPK activated transcription factor AP‐1 is responsible for proteasome inhibitor‐induced maspin expression. Taken together, these observations demonstrate that proteasome inhibitors induce maspin expression by activating p38MAPK pathway, and that maspin thus expressed, in turn, augments proteasome inhibitor‐induced apoptosis in prostate cancer cells. Our results suggest that gene therapy involving ectopic maspin expression may dramatically improve the efficacy of proteasome inhibitors for the treatment of prostate cancer. J. Cell. Physiol. 212: 298–306, 2007. © 2007 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract Many tumors constitutively express high levels of the inducible form of proinflammatory enzyme, cyclooxygenase‐2 (COX‐2). Increased COX‐2 expression is associated with tumor cell resistance to many cytotoxic chemotherapy drugs. Furthermore, increased resistance to cytotoxic antitumor dr
## Abstract Prostate cancer is associated with the inability of prostatic epithelial cells to undergo apoptosis rather than with increased cell proliferation. Prostate apoptosis response‐4 (Par‐4) is a unique pro‐apoptotic molecule that is capable of selectively inducing apoptosis in cancer cells w
## Abstract In the treatment of colon cancer, the development of resistance to apoptosis is a major factor in resistance to therapy. New molecular approaches to overcome apoptosis resistance, such as selectively upregulating proapoptotic proteins, are needed in colon cancer therapy. In a mouse mode
## Abstract Anticancer drugs docetaxel and vinorelbine suppress cell growth by altering microtubule assembly and activating the proapoptotic signal pathway. Vinorelbine and docetaxel have been approved for treating several advanced cancers. However, their efficacy in the management of advanced horm
Polypeptide growth factors are positive and negative regulators of prostatic growth and function, and many positive regulators of growth in the prostate have been extensively studied. However, very few inhibitors of prostate cell proliferation have been identified. We have isolated a unique 18-kDa s